To include your compound in the COVID-19 Resource Center, submit it here.

Amgen's Repatha beats sales estimates in 2Q17

Amgen Inc. (NASDAQ:AMGN) reported 2Q17 earnings that topped estimates, including sales of hypercholesterolemia drug Repatha evolocumab that exceeded expectations.

Repatha's sales rose to $83

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE